Workflow
联环药业涨2.03%,成交额3.31亿元,主力资金净流入1260.89万元

Group 1 - The core viewpoint of the news is that Lianhuan Pharmaceutical has shown significant stock performance with a year-to-date increase of 140.30%, despite a recent decline of 4.07% over the last five trading days [1] - As of August 29, Lianhuan Pharmaceutical's stock price reached 23.60 yuan per share, with a total market capitalization of 6.737 billion yuan [1] - The company has been actively traded, with a net inflow of main funds amounting to 12.6089 million yuan and significant trading volumes in large orders [1] Group 2 - Lianhuan Pharmaceutical operates in the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and preparations, and is categorized under several concept sectors including small-cap and biomedicine [2] - For the first half of 2025, Lianhuan Pharmaceutical reported a revenue of 1.285 billion yuan, reflecting a year-on-year growth of 14.12%, while the net profit attributable to the parent company was -40.0284 million yuan, a decrease of 163.65% [2] - The company has distributed a total of 343 million yuan in dividends since its A-share listing, with 111 million yuan distributed over the past three years [3]